PLRZ

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled "Mucoadhesive Polymers for Nasal Drug Delivery". The patent application covers Polyrizon's proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling mo

6-K - Polyrizon Ltd. (0001893645) (Filer)

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the execution of an agreement with a leading, internationally recognized European university medical center, alongside a contract with a specialized clinical research organization (CRO), to conduct a human study as part of its verification and validation (V&V)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO) has completed the technical preparations for the publication of the Company's European patent application entitled "Mucoadhesive Polymers for Nasal Drug Delivery." The application was published under European publication number EP 4751737. The patent application covers Polyrizon's proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the inte

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study. These three sites represent the largest and most strategically important centers in the Company's planned multi-center clinical trial and are expected to contribute the highest rates of patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the NASARIX™ Allergy B

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site specializing in allergy studies, marking a key milestone toward the initiation of its clinical program for the NASARIXTM (PL-14) Allergy Blocker. The clinical site, located in Texas, will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the NASARIXTM Allergy Blocker in patients wit

In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may offer immediate, non-specific defense at the nasal gatewayHONG KONG, May 11, 2026 /PRNewswire/ -- Recent World Health Organization reports of Hantavirus clusters, including clusters of severe acute respiratory illness, have once again served as a stark reminder: the next major viral threat is never far away. Whether it is Hantavirus, a novel coronavirus variant, or an unexpected influenza strain, the pattern is consistent. Outbreaks emerge quickly, and the window for effective intervention is narrow. In these critical early we

EFFECT - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of amended claims in its U.S. patent application for its proprietary intranasal drug delivery platform. The amended claims expand the scope of protection of the Company's technology to include not only the core mucoadhesive composition, but also drug delivery systems and methods of use, which are designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. This developmen

F-1/A - Polyrizon Ltd. (0001893645) (Filer)

SCHEDULE 13G - Polyrizon Ltd. (0001893645) (Subject)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Europe Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company's advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company's recently announced U.S. patent application which encompass

D - Polyrizon Ltd. (0001893645) (Filer)

F-1 - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

424B5 - Polyrizon Ltd. (0001893645) (Filer)